No Data
No Data
jointown pharmaceutical group (600998.SH): to privately issue preferred shares for listing transfer.
Jointown Pharmaceutical Group (600998.SH) announced on September 18th that, with the approval of the Shanghai Stock Exchange, the preferred shares issued by the company will be listed for transfer on the Shanghai Stock Exchange Comprehensive Business Platform starting from September 24th, 2024.
Jointown Pharmaceutical Group (SHSE:600998) Stock Falls 6.9% in Past Week as Three-year Earnings and Shareholder Returns Continue Downward Trend
Jointown Pharmaceutical Group (600998.SH): Furosemide has obtained the notice of approval for the marketing application of chemical raw materials.
Jointown Pharmaceutical Group (600998.SH) announced on September 11th that its subsidiary, Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the Approval Notice for the Application of Listing Chemical Raw Materials Pharmaceuticals issued by the National Medical Products Administration on September 10th, 2024, approving the application for the market launch of furosemide. Furosemide is a potent diuretic used primarily to treat edema caused by heart, liver, kidney, and other diseases. It increases the excretion of water, sodium, chloride, potassium, calcium, magnesium, phosphorus, and other substances to achieve a diuretic effect. Furosemide preparations play an important role in the cardiovascular field, including furosemide injections, furosemide tablets, and furosemide for injection.
A subsidiary has been "blacklisted" by Shenzhen for one year. Jointown Pharmaceutical Group claims to be "in the process of defending". The industry believes that the intensity of procurement supervision is continuously increasing.
Recently, Jointown Pharmaceutical Group's subsidiary, Jointown Medical Device, was fined and banned from participating in Shenzhen procurement for one year due to providing false information in a tender at a hospital in Shenzhen. Jointown Pharmaceutical Group responded to a reporter from Caijing.com.cn, stating that this incident is a pending matter, and they have organized appeal materials and are currently undergoing administrative reconsideration. This year, several listed companies have been fined for violations in the bidding and procurement process, leading industry insiders to suggest that companies should pay more attention to compliance with details during the bidding process.
Ping An Health and Jointown Health Technology have reached a strategic cooperation, bringing together new productive forces of medical and health technology.
Recently, Ping An Health Medical Technology Co., Ltd. (stock abbreviation "Ping An Good Doctor", 1833.HK, hereinafter referred to as "Ping An Health") and Jointown Pharmaceutical Group (hereinafter referred to as "Jointown Pharmaceutical Group") officially announced the establishment of a strategic partnership. Wu Jun, President of Ping An Health, Zheng Bosong, Senior Vice President of Ping An Health, and Liu Jinghan, CEO of Jointown Pharmaceutical Group, attended the event. This cooperation not only represents the strong alliance of the two parties in the field of medical and health, but also an innovative development and in-depth exploration of the new model of "Internet + medical + pharmaceutical", aiming to provide more convenient and high-quality services to users.
Jointown Pharmaceutical Group (600998.SH): In August, the company did not repurchase stocks through centralized competitive trading.
On August 2, Jointown Pharmaceutical Group (600998.SH) announced that in August 2024, the company did not repurchase stocks through the centralized bidding trading method. As of August 30, 2024, the company has cumulatively repurchased 54.0805 million shares, accounting for 1.07% of the total share capital of the company. The highest purchase price was 5.18 yuan/share, and the lowest price was 4.42 yuan/share. The total amount paid was 258.8364 million yuan (excluding commission and fees). The company's stock repurchase progress complies with relevant laws, regulations, and the company's repurchase plan.
No Data
No Data